- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Agilent Technologies prepares for IPO
Newly spun-off Hewlett-Packard healthcare operation Agilent Technologies has filed a registration statement with the Securities and Exchange Commission for a proposed public offering, the company has announced. Agilent will offer 57 million shares of
Newly spun-off Hewlett-Packard healthcare operation Agilent Technologies has filed a registration statement with the Securities and Exchange Commission for a proposed public offering, the company has announced. Agilent will offer 57 million shares of common stock, 45.6 million offered in the U.S. and Canada, and 11.4 million of which will be offered internationally. Estimated IPO price per share is between $19 and $22, according to Agilent. Morgan Stanley Dean Witter and Goldman, Sachs & Company are handling the offering.
In March, Palo Alto, CA-based Hewlett-Packard spun off its medical products group, along with four other businesses, in an effort to focus on its computer business (SCAN 3/17/99). The name Agilent Technologies was chosen for the $8 billion Andover, MA, company in August (SCAN 8/4/99).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
